A large-scale NHS trial investigating the efficacy of the Galleri multi-cancer blood test has reportedly failed to meet its primary objective. The study, which involved 142,000 patients across the UK, aimed to determine if the innovative blood test could reduce the incidence of late-stage cancer diagnoses. However, data presented at a prominent oncology conference in Chicago indicated that the test did not achieve this crucial goal.
The Galleri test, developed by GRAIL, is designed to detect DNA fragments shed by tumours into the bloodstream, potentially identifying more than 50 types of cancer at earlier stages. Hailed by some as a potential 'holy grail' in oncology, the premise was that earlier detection could lead to more effective treatments and improved patient outcomes, particularly for cancers that are typically diagnosed at an advanced stage due to a lack of early symptoms or screening programmes.
The study, known as the SYMPLIFY trial, was a randomised controlled trial comparing a group who received the Galleri test with a control group receiving standard NHS care. While the test did identify some cancers, the overall impact on the proportion of late-stage diagnoses within the trial population did not reach the pre-defined target. This outcome will undoubtedly prompt further scrutiny and analysis of the data.
For the NHS, the implications of these findings are significant. The health service has been under immense pressure to improve cancer outcomes, with targets often missed and lengthy waiting lists for diagnostic tests and treatments. A test that could reliably detect multiple cancers early was seen as a potential game-changer, easing diagnostic bottlenecks and potentially saving lives. The current results suggest that while the technology holds promise, its immediate application in a widespread screening programme for reducing late-stage diagnoses may require further refinement or a different approach.
It is important to note that while the primary endpoint was not met, researchers will continue to analyse secondary endpoints and other aspects of the trial data. This ongoing analysis may reveal other benefits or specific use cases for the Galleri test, even if its broad application for reducing late-stage diagnoses across a general population proves more complex than initially hoped. The challenge of developing effective multi-cancer early detection tests remains a priority for medical science.
Source: Oncology conference in Chicago